Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195242 | 0.86 | TGM2 (0.61) | SMN1; SMN2LMNATGM2MAPTHTT | |
| SCHEMBL10244942 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAMAPTHTTNPC1 | |
| SCHEMBL21570876 | 0.79 | TSHR (0.48) | SMN1; SMN2MAPTHTTRAB9AFAAH | |
| SCHEMBL3443629 | 0.79 | NPC1 (0.69) | SMN1; SMN2LMNAMAPTNPC1RAB9A | |
| SCHEMBL28631639 | 0.78 | TGM2 (0.44) | SMN1; SMN2LMNATGM2MAPTGAA | |
| SCHEMBL23111386 | 0.78 | TSHR (0.46) | SMN1; SMN2MAPTHTTRAB9AFAAH | |
| SCHEMBL318098 | 0.77 | THRB (0.61) | SMN1; SMN2LMNATEAD3ALDH1A1 | |
| SCHEMBL9068033 | 0.77 | CASP1 (0.55) | SMN1; SMN2LMNATGM2MAPTALDH1A1 | |
| SCHEMBL9825023 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2LMNATGM2GAAHTT | |
| SCHEMBL97680 | 0.76 | NPC1 (0.57) | SMN1; SMN2LMNAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | SMN1; SMN2 3120/4885LMNA 1467/4885TGM2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.